ArticleMolecular pharmaceutics2013
Fibrin-targeted PET probes for the detection of thrombi.
Article in Molecular pharmaceutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 59 citations in OpenAlex.
- Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Brain-penetrating peptide and antibody radioligands for proof-of-concept PET imaging of fibrin in Alzheimer's disease.EJNMMI radiopharmacy and chemistry · 2025Article
- First-in-human Evaluation of Safety and Dosimetry of [Molecular imaging and biology · 2025Article
- Inductively Coupled Plasma-Mass Spectrometry (ICP-MS): An Emerging Tool in Radiopharmaceutical Science.Journal of the American Chemical Society · 2024Review
- Dosimetry of [medRxiv : the preprint server for health sciences · 2024Article
- Nanoparticles for Thrombus Diagnosis and Therapy: Emerging Trends in Thrombus-theranostics.Nanotheranostics · 2024Review
- Molecular Detection of Venous Thrombosis in Mouse Models Using SPECT/CT.Biomolecules · 2022Article
- Engineered Molecular Therapeutics Targeting Fibrin and the Coagulation System: a Biophysical Perspective.Biophysical reviews · 2022Review
- Article
- Imaging High-Risk Atherothrombosis Using a Novel Fibrin-Binding Positron Emission Tomography Probe.Stroke · 2022Article
- Multi-Scale Imaging of Vascular Pathologies in Cardiovascular Disease.Frontiers in medicine · 2021Review
- Nano-Medicine for Thrombosis: A Precise Diagnosis and Treatment Strategy.Nano-micro letters · 2020Review
- Current Applications for Nuclear Medicine Imaging in Pulmonary Disease.Current pulmonology reports · 2020Review
- Imaging evaluation of acute ischemic stroke.The Journal of international medical research · 2020Article
- A Comprehensive Review of Non-Covalent Radiofluorination Approaches Using Aluminum [Molecules (Basel, Switzerland) · 2019Review
- An unmet clinical need: The history of thrombus imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2019Review
- Radionuclide Imaging of Atherothrombotic Diseases.Current cardiovascular imaging reports · 2019Article
- Polydopamine-modified dual-ligand nanoparticles as highly effective and targeted magnetic resonance/photoacoustic dual-modality thrombus imaging agents.International journal of nanomedicine · 2019Article
- Synthesis and Preclinical Evaluation of the Fibrin-Binding Cyclic PeptideContrast media & molecular imaging · 2019Article
- Metabolite profiling with HPLC-ICP-MS as a tool for in vivo characterization of imaging probes.EJNMMI radiopharmacy and chemistry · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
There is an ongoing effort to develop better methods for noninvasive detection and characterization of thrombi. Here we describe the synthesis and evaluation of three new fibrin-targeted positron emission tomography (PET) probes (FBP1, FBP2, FBP3). Three fibrin-specific peptides were conjugated as 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-monoamides at the C- and N-termini and chelated with (64)CuCl2. Probes were prepared with a specific activity ranging from 10 to 130 μCi/nmol. Both the peptides and the probes exhibited nanomolar dissociation constants (Kd) for the soluble fibrin fragment DD(E), although the Cu-DOTA derivatization resulted in a 2-3 fold loss in affinity relative to the parent peptide. Biodistribution and imaging studies were performed in a rat model of carotid artery thrombosis. For FBP1 and FBP2 at 120 min post injection, the vessel containing the thrombus showed the highest concentration of radioactivity after the excretory organs, that is, the liver and kidneys. This was confirmed ex vivo by autoradiography, which showed >4-fold activity in the thrombus-containing artery compared to the contralateral artery. FBP3 showed much lower thrombus uptake, and the difference was traced to greater metabolism of this probe. Hybrid MR-PET imaging with FBP1 or FBP2 confirmed that these probes were effective for the detection of an arterial thrombus in this rat model. A thrombus was visible on PET images as a region of high activity that corresponded to a region of arterial occlusion identified by simultaneous MR angiography. FBP1 and FBP2 represent promising new probes for the molecular imaging of thrombi.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.